On the other hand, ICI combination therapies have been approved for the treatment of metastatic melanoma, advanced or metastatic RCC, MSI-H colorectal cancer that has progressed after chemotherapy, advanced HCC, driver-gene-negative NSCLC with PD-L1 expression ≥ 1%, and unresectable MPM. This evidence concerns the gene CD274 and renal cell carcinoma.